Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
NCT02343666 · Fred Hutchinson Cancer Center · PHASE1 · withdrawn · last registry update 2018-11-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Administrative closure prior to any enrollments” | – | Registry record, Fred Hutchinson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-08-28Also stopped (terminated): M.D. Anderson Cancer Center, Plerixafor + Clofarabine (NCT01160354)
- 2019-06-27Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Preparative regimen (NCT04000698)
- 2019-06-21Phase 3 first posted: X4 Pharmaceuticals, Mavorixafor + Placebo (NCT03995108)
- 2019-06-14Results posted on the registry: Case Comprehensive Cancer Center, plerixafor + filgrastim (NCT01408043)
- 2019-06-14Also stopped (terminated): Case Comprehensive Cancer Center, plerixafor + filgrastim (NCT01408043)
- 2019-05-10Results posted on the registry: M.D. Anderson Cancer Center, Plerixafor + Clofarabine (NCT01160354)
- 2019-04-23Results posted on the registry: M.D. Anderson Cancer Center, Filgrastim + Plerixafor (NCT01818284)
- 2019-03-15Results posted on the registry: Memorial Sloan Kettering Cancer Center, lenalidomide and dexamethasone (NCT00807599)
- 2019-01-18Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Burixafor Hydrobromide + Docetaxel (NCT02478125)
- 2018-12-28Results posted on the registry: Fred Hutchinson Cancer Center, Carmustine + Filgrastim (NCT00669669)
- 2018-12-24Phase 3 first posted: Spexis AG, Eribulin + Balixafortide (NCT03786094)
- 2018-12-07Also stopped (terminated): X4 Pharmaceuticals, X4P-001 (NCT02680782)
- 2018-11-01Also stopped (terminated): Bristol-Myers Squibb, Ulocuplumab + Nivolumab (NCT02472977)
- 2018-07-31Also stopped (terminated): University of California, San Francisco, Transplant Conditioning with Mobilization Only + Transplant Conditioning with Mobilization and Alemtuzumab (NCT01182675)
- 2018-07-12Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), 64-Cu-plerixafor (NCT02069080)
- 2018-07-03Results posted on the registry: Lawrence Recht, temozolomide + plerixafor (NCT01977677)
- 2018-03-29Results posted on the registry: Bristol-Myers Squibb, Ulocuplumab + Nivolumab (NCT02472977)
- 2018-02-07Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), AMD3100 (Mozobil plerixafor) (NCT00075335)
- 2018-02-05Results posted on the registry: David Rizzieri, MD, Lenalidomide + Plerixafor (+ Rituximab) (NCT01373229)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision